Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have earned an average recommendation of “Moderate Buy” from the twenty-six ratings firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation, eighteen have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $950.76.

Several research analysts have commented on REGN shares. JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a research note on Monday, March 31st. Bank of America reduced their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a research note on Thursday, April 17th. Piper Sandler cut their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a report on Monday, January 27th. The Goldman Sachs Group decreased their price target on shares of Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a “buy” rating on the stock in a report on Monday, April 14th. Finally, Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Pinney & Scofield Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $25,000. Rakuten Securities Inc. grew its position in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 15 shares during the last quarter. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $28,000. Avalon Trust Co purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $36,000. Finally, Crowley Wealth Management Inc. bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $36,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN opened at $585.49 on Wednesday. The firm has a 50-day moving average price of $642.12 and a 200-day moving average price of $732.33. Regeneron Pharmaceuticals has a twelve month low of $525.99 and a twelve month high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $64.01 billion, a price-to-earnings ratio of 15.29, a PEG ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $11.86 EPS. Equities analysts expect that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.